Long-Term Allergy Treatment: The Only Option That Stops Working After You Stop
The only long-term allergy treatment with randomized-trial evidence for durable post-treatment remission is allergen immunotherapy — SCIT (3-5 year injection course) or SLIT (daily sublingual). Cox, Murphey, and Hankin (Immunol Allergy Clin North Am 2020, PMID 31761122) confirm SCIT is the only disease-modifying allergy therapy. Durham 1999 NEJM: 3-year course produces 4 additional symptom-free years. Daily antihistamines, nasal sprays, and biologics manage symptoms but provide no durability after stopping.
7 peer-reviewed sources
The only long-term allergy treatments with durable post-treatment remission are SCIT (injection course) and SLIT (sublingual). Antihistamines, nasal corticosteroids, and biologics provide effective long-term management but symptoms return on discontinuation — they are not disease-modifying.
The essentials
Long-term allergy treatment divides into two clinically distinct categories. In the first category are treatments that manage allergy over the long term but do not change the underlying disease: daily intranasal corticosteroids (fluticasone propionate, mometasone furoate, triamcinolone, budesonide, beclomethasone), daily second-generation oral antihistamines (loratadine, cetirizine, fexofenadine, desloratadine, levocetirizine), and biologic injections (Xolair/omalizumab anti-IgE; Dupixent/dupilumab anti-IL-4Rα; Tezspire/tezepelumab-ekko anti-TSLP). All of these work well while you take them, but symptoms return when discontinued — they are long-term management without induced tolerance.
In the second category is allergen immunotherapy — SCIT (the 3-to-5-year subcutaneous injection course per Cox 2011 PP3, JACI 2011;127[1 Suppl]:S1-S55) and SLIT (sublingual drops or FDA-approved tablets). These are the only interventions classified as disease-modifying in any peer-reviewed analysis. Cox L, Murphey A, and Hankin C (Immunol Allergy Clin North Am 2020;40[1]:69-85, PMID 31761122) explicitly state that SCIT is the only allergy treatment with long-term remission documented in randomized controlled trials.
The foundational RCT for long-term remission is Durham SR et al (NEJM 1999;341:468-475, PMID 10441602). Grass-pollen-allergic patients who completed a 3-year SCIT course were followed for 4 additional years after discontinuation. Their symptom and medication scores at 4 years off treatment remained as low as patients who had continued receiving injections throughout — demonstrating that the 3-year course produces lasting immune change.
Before starting any long-term immunotherapy course, identifying which allergens are driving symptoms is the essential prerequisite. Curex pairs at-home IgE testing with allergist review to identify which allergens drive symptoms, so the long-term treatment plan targets the right targets — the same diagnostic prerequisite as Cox 2011 SCIT initiation.
The practical decision point for patients is whether they are willing to commit 3-to-5 years upfront for a disease-modifying outcome, or prefer ongoing daily/biweekly treatment that provides excellent symptom control while maintained. Both approaches are clinically valid; only immunotherapy offers the option to eventually stop treatment and maintain benefit.
Ready to skip the surprise bills?
See if at-home allergy shots fit your allergies — a 2-minute quiz, designed by board-certified allergists, with flat monthly pricing and no clinic visits.
- 4.8/5Patient rating
- $129/moFlat pricing
- 50K+Patients treated
- HSA/FSAEligible
Efficacy by allergen — what the data shows
Long-term durability is the defining advantage of immunotherapy over pharmacotherapy. The evidence base: Calderón MA et al (Cochrane 2007, 51 RCTs, 2,871 patients) found SCIT produces symptom SMD -0.73 during treatment. Durham SR et al (NEJM 1999) documented that this benefit persists for at least 4 years after stopping a 3-year course. No comparable post-discontinuation data exists for antihistamines, nasal corticosteroids, or biologics — because all three return to pre-treatment symptom levels within days to weeks of stopping.
Same proven results. No clinic visits.
Curex's at-home allergy shots deliver the same allergen desensitization as clinic SCIT — for a flat $129/month, with no clinic visits and no facility fees.
See if at-home shots are right for youTreatment options side by side
The long-term treatment spectrum ranges from ongoing daily management (no durability after stopping) to multi-year disease-modifying courses (durable remission after stopping). The right choice depends on patient preference for ongoing treatment versus a defined endpoint.
| Treatment | Efficacy | Duration | Cost (5yr) | Convenience | Safety |
|---|---|---|---|---|---|
At-Home Allergy Shots (Curex SCIT) | |||||
SLIT drops (home sublingual) | |||||
Intranasal corticosteroids (fluticasone, mometasone) | |||||
Biologics (Xolair, Dupixent, Tezspire) |
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
For patients pursuing the only disease-modifying long-term option, Curex delivers the same SCIT immunotherapy as one weekly shot you give yourself at home for $129/month — a personalized serum sterile-compounded to USP <797>, prescribed by a board-certified allergist, with your first dose and every dose change supervised live over Zoom, so the full course finishes without 39 Year-1 clinic visits.
See if at-home shots are right for youFrequently asked questions
Is there a long-term allergy treatment that actually works?
Yes. Allergen immunotherapy — subcutaneous immunotherapy (SCIT, the 3-to-5-year injection course) or sublingual immunotherapy (SLIT) — is the only category of allergy treatment classified as disease-modifying in peer-reviewed literature. Cox L, Murphey A, and Hankin C (Immunol Allergy Clin North Am 2020;40[1]:69-85, PMID 31761122) explicitly stated that SCIT is the only allergy therapy with long-term remission documented in randomized trials. Durham SR et al (NEJM 1999) confirmed that a 3-year grass-pollen SCIT course produced 4 additional years of symptom-free outcomes after stopping — no pharmacotherapy produces comparable post-discontinuation benefit.
How long does long-term allergy treatment (SCIT) last?
A complete SCIT course requires 3-5 years of treatment per Cox 2011 PP3: approximately 6 months of weekly build-up injections (~26-28 visits) followed by 2.5-4.5 years of every 2-4 week maintenance injections. Year 1 involves approximately 39 total clinic visits. After completing the full course, no further injections are typically required. Post-treatment durable remission lasts an average of 4-12 years based on Durham 1999 NEJM and observational follow-up data. For long-term management without a defined endpoint, antihistamines and nasal corticosteroids require indefinite daily use.
Do antihistamines work as a long-term allergy treatment?
Second-generation antihistamines (loratadine, cetirizine, fexofenadine) are effective long-term symptom management when taken daily but are not disease-modifying. They block histamine H1 receptors, reducing the immediate allergic response, but they do not change the underlying IgE sensitization or reduce mast-cell and eosinophil counts in target tissues. When antihistamines are stopped, symptoms return because the allergic immune program has not been changed. Cost-effectiveness analyses show that antihistamines are far cheaper and have vastly better real-world adherence than SCIT, making them appropriate for mild-to-moderate allergic disease or as complementary treatment during the early SCIT build-up phase.
Are biologics like Xolair a long-term cure for allergies?
Biologics like Xolair (omalizumab), Dupixent (dupilumab), and Tezspire (tezepelumab) are effective long-term disease controllers for specific conditions — Xolair for persistent allergic asthma, chronic spontaneous urticaria, and IgE-mediated food allergy; Dupixent for atopic dermatitis and asthma; Tezspire for severe asthma. However, they are not cures and do not induce allergen-specific tolerance. Symptoms return when biologics are discontinued. This is clinically confirmed — unlike SCIT, which has post-discontinuation remission data, no biologic has documented disease-free status years after stopping the drug.
What is the best long-term treatment for seasonal allergies?
For patients with seasonal allergic rhinitis due to confirmed IgE sensitization to a treatable allergen (grass pollen, ragweed, tree pollen, dust mite), allergen immunotherapy — SCIT or SLIT — is the only option with documented post-treatment durability. Cochrane meta-analysis (Calderón 2007, 51 RCTs) found SCIT produces symptom SMD -0.73 versus placebo during treatment; Durham 1999 NEJM showed 4-year post-treatment remission. For patients unable or unwilling to commit to 3-5 years of treatment, high-quality symptom control is achievable with daily intranasal corticosteroids (most effective single pharmacotherapy for nasal symptoms) combined with as-needed antihistamines.
Can children undergo long-term allergy immunotherapy?
Yes. Cox 2011 PP3 supports SCIT in children aged 5 years and older. The pediatric case is particularly compelling because early immunotherapy may prevent asthma development — the PAT study (Jacobsen L et al, Allergy 2007;62:943-948) found that a 3-year pollen SCIT course in allergic-rhinitis children reduced subsequent asthma incidence by approximately half at 10-year follow-up. Möller C et al (JACI 2002) confirmed the asthma-prevention signal. This long-term pediatric benefit — preventing a new disease from developing — represents the most compelling argument for early initiation and is not produced by any pharmacotherapy.
Related Articles
Allergy Shots: The Complete Patient Guide to SCIT | Curex
Allergy shots (SCIT) are the only FDA-recognized disease-modifying allergy treatment. Learn who qualifies, how they work, and what alternatives exist.
Read moreTired After Allergy Shots — What the Data Shows | Curex
Fatigue after allergy shots is real and patient-reported — but no peer-reviewed surveillance quantifies its prevalence. Here is what is actually known and what is not.
Read moreAllergy Treatment Shots: SCIT Evidence Guide | Curex
Allergy treatment shots (SCIT): ~39 Year-1 visits per Cox 2011. Cochrane SMD -0.73. Durham 1999: 3-yr course, 4-yr remission. Who qualifies inside.
Read moreAllergy Shot For Humans: SCIT & SLIT Guide
Yes, there is an allergy shot for humans — subcutaneous immunotherapy (SCIT). Cochrane SMD −0.73, 3–5 yr course, at home via Curex $129/mo. Not Cytopoint.
Read moreAllergy Medicine Injection: SCIT vs Biologics vs Steroids | Curex
Allergy medicine injections include SCIT (allergen extract — not a drug), Xolair, Dupixent, and depot steroids. SCIT is the only option with 4-yr post-treatment remission per NEJM 1999.
Read moreAllergy Injection Medication: Complete Category Guide | Curex
Allergy injection medications include SCIT (allergen extract), Xolair, Dupixent, Tezspire, depot steroids, and epinephrine. Only SCIT modifies disease. FDA approval dates and evidence.
Read moreGet your allergy shots — without the clinic.
Curex's flat $129/month covers end-to-end at-home immunotherapy — a personalized serum compounded to USP <797> sterile standards, board-certified allergist oversight, and one weekly injection you give yourself at home. No clinic visits, no facility fees. HSA/FSA eligible.
$129/mo flat · No facility fees · HSA/FSA eligible · Cancel anytime
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.